Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity

Autoimmunity Reviews

Volumn 12, Issue 10, 2013, Pages 972-975

  Askenasy, Nadir ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Activation induced cell death; Autoimmunity; Fas cross linking; Inflammation; Regulatory T cells

Indexed keywords

CASPASE 3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CHEMORADIOTHERAPY; DISEASE COURSE; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; NONHUMAN; PATHOGEN LOAD; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

ACTIVATION INDUCED CELL DEATH; AUTOIMMUNITY; FAS CROSS-LINKING; INFLAMMATION; REGULATORY T CELLS;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOMODULATION; INFLAMMATION; T-LYMPHOCYTES, REGULATORY;

EID: 84880599593     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.04.005     Document Type: Review

References (56)

1. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6:338-344.
2. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
3. + regulatory T cells. Immunol Rev 2006, 212:60-73.
4. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007, 13:108-116.
5. Askenasy N., Kaminitz A., Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008, 7:370-375.
6. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
7. Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T. Regulatory T cells: how do they suppress immune responses?. Int Immunol 2009, 21:1105-1111.
8. Langier S., Sade K., Kivity S. Regulatory T cells: the suppressor arm of the immune system. Autoimmun Rev 2010, 10:112-115.
9. Shevach E.M. Biological functions of regulatory T cells. Adv Immunol 2011, 112:137-176.
10. + T cells. Nat Immunol 2007, 8:1353-1362.
11. + Treg cell homeostasis in Type I diabetes. Autoimmun Rev 2011, 11:104-111.
12. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
13. Bryl E., Daca A., Jóźwik A., Witkowski J.M. Human CD4(low)CD25(high) regulatory T cells indiscriminately kill autologous activated T cells. Immunology 2009, 128:e287-e295. [Suppl.].
14. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005, 174:1783-1786.
15. + T cells selectively kill B lymphocytes. Blood 2006, 107:3925-3932.
16. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+) CD25 (+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001, 194:629-644.
17. Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21:503-513.
18. Pan X., Marson A.L., Zhou G., Pan X., Marson A.L., Zhou G., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21:503-513.
19. + regulatory T cell function. Eur J Immunol 2004, 34:2996-3005.
20. + regulatory T cells abrogates their function in vivo. J Immunol 2006, 177:4376-4383.
21. + T cells. Blood 2007, 109:2058-2065.
22. Chen W., Ford M.S., Young K.J., Zhang L. The role and mechanisms of double negative regulatory T cells in the suppression of immune responses. Cell Mol Immunol 2004, 1:328-335.
23. + T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003, 171:4604-4612.
24. Weber S.E., Harbertson J., Godebu E., Mros G.A., Padrick R.C., Carson B.D., et al. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol 2006, 176:4730-4739.
25. Weiss E.M., Schmidt A., Vobis D., Garbi N., Lahl K., Mayer C.T., et al. Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol 2011, 187:1684-1691.
26. + regulatory T cells. Cell Death Differ 2007, 14:2076-2084.
27. + regulatory T cell survival. Biol Direct 2008, 3:6.
28. Yolcu E.S., Ash S., Kaminitz A., Sagiv Y., Askenasy N., Yarkoni S. Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol 2008, 86:650-658.
29. Kaminitz A., Yolcu E.S., Askenasy E.M., Stein J., Yaniv I., Shirwan H., et al. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLoS One 2011, 6:e21630.
30. + T cell subsets is dominated by cytokine deprivation and absence of other cells in new onset diabetic NOD mice. PLoS One 2010, 5:e15684.
31. Yolcu E.S., Askenasy N., Singh N.P., Cherradi S.E., Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002, 17:795-808.
32. Askenasy N., Yolcu E.S., Yaniv I., Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 2005, 105:1396-1404.
33. Kaminitz A., Yolcu E.S., Stein J., Yaniv I., Shirwan H., Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun 2011, 37:39-47.
34. Kaminitz A., Yolcu E.S., Mizrahi K., Shirwan H., Askenasy N. Killer regulatory T cells ameliorate inflammatory insulitis in diabetic NOD mice through local and systemic immunomodulation. Int Immunol 2013, [in press]. 10.1093/intimm/dxt016.
35. Kaminitz A., Askenasy N., Yolcu E.S. Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis. Gut 2013, [in press]. 10.1136/gutjnl-2012-304432.
36. Yolcu E.S., Kaminitz A., Mizrahi K., Yaniv I., Stein J., Shirwan H., et al. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft versus host disease. Exp Hematol 2013, [in press].
37. Franke D.D., Yolcu E.S., Alard P., Kosiewicz M.M., Shirwan H. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol Immunol 2007, 44:2884-2892.
38. Askenasy N., Mizrahi K., Ash S., Askenasy E.M., Yaniv I., Stein J. Depletion of naïve lymphocytes with Fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity. Biol Blood Marrow Transplant 2013, 19:185-195.
39. Yarkoni S., Sagiv Y., Kaminitz A., Farkas D.L., Askenasy N. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis. Eur J Immunol 2009, 39:2850-2864.
40. Yarkoni S., Kaminitz A., Sagiv Y., Askenasy N. Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice. Diabetologia 2010, 53:356-368.
41. Yarkoni S., Prigozhina T.B., Slavin S., Askenasy N. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. Biol Blood Marrow Transplant 2012, 18:523-535.
42. Sagiv Y., Kaminitz A., Lorberboum-Galski H., Askenasy N., Yarkoni S. A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis. Ann N Y Acad Sci 2009, 1173:791-797.
43. Yarkoni S., Kaminitz A., Sagiv Y., Yaniv I., Askenasy N. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2cycle. Bioessays 2008, 30:875-888.
44. Kaminitz A., Mizrahi K., Yaniv I., Stein J., Askenasy N. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun 2010, 35:145-152.
45. Yaniv I., Ash S., Farkas D.L., Askenasy N., Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 2009, 33:255-259.
46. Askenasy E.M., Askenasy N., Askenasy J.J. Does lymphopenia preclude restoration of immune homeostasis ? The particular case of type 1 diabetes. Autoimmun Rev 2010, 9:687-690.
47. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
48. Antico A., Tampoia M., Tozzoli R., Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012, 12:127-136.
49. + regulatory T cells in systemic autoimmune disease. Autoimmun Rev 2011, 10:744-755.
50. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 2012, 12:300-304.
51. Kessel A., Haj T., Peri R., Snir A., Melamed D., Sabo E., et al. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 2012, 11:670-677.
52. von Herrath M., Sanda S., Herold K. Type 1 diabetes as a relapsing-remitting disease?. Nat Rev Immunol 2007, 7:988-994.
53. Peakman M., von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010, 59:2087-2093.
54. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12:436-443.
55. Sawla P., Hossain A., Hahn B.H., Singh R.P. Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance. Autoimmun Rev 2012, 11:611-614.
56. Gertel-Lapter S., Mizrachi K., Berrih-Aknin S., Fuchs S., Souroujon M.C. Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model. Autoimmun Rev 2013, 12:894-903.